• Targeting DHHC9-Mediated Palmitoylation to Limit YAP-Driven

  2026-05-06

  This study uncovers DHHC9-mediated palmitoylation of STRN4 as a critical driver of YAP-dependent cancer metastasis. Through genetic and pharmacological inhibition, the research demonstrates that targeting this pathway effectively suppresses metastatic behaviors, highlighting DHHC9 as a promising therapeutic target for adenocarcinoma.

• Poly-GA Drives Tau Pathology via ERK1/2: U0126 Reveals Mecha

  2026-05-05

  This study identifies poly-glycine-alanine (poly-GA) as a direct activator of ERK1/2, amplifying tau phosphorylation and aggregation in C9orf72-linked frontotemporal lobar degeneration (FTLD). Pharmacological inhibition of ERK1/2 using U0126 robustly attenuates tau pathology and cell death, delineating a mechanistic link and highlighting potential therapeutic strategies.

• 2-APB and the ER-Ca2+-Calpain Axis: Precision Tools for Auto

  2026-05-05

  Explore how 2-APB (2-aminoethoxydiphenyl borate) enables advanced dissection of ER-calcium signaling and programmed cell death transitions. This article unveils unique mechanistic insights and practical assay guidance for researchers investigating autophagy, apoptosis, and oxidative stress.

• DiscoveryProbe Protease Inhibitor Library: Optimizing HTS Wo

  2026-05-04

  The DiscoveryProbe™ Protease Inhibitor Library empowers researchers with 825 rigorously validated, cell-permeable compounds for high throughput and high content screening. Its diversity and automation-ready format accelerate discovery in apoptosis, cancer, and infectious disease research while supporting reproducible, mechanistically focused assays.

• 25-Hydroxycholesterol Orchestrates Immunosuppressive Macroph

  2026-05-04

  Xiao et al. reveal that tumor-associated macrophages (TAMs) accumulate 25-hydroxycholesterol (25HC), which activates lysosomal AMPKα through a GPR155-mTORC1 mechanism, directly modulating STAT6 phosphorylation and promoting immunosuppression. This work uncovers CH25H-25HC as an immunometabolic checkpoint and suggests that targeting this axis can potentiate anti-tumor immunity, especially in conjunction with anti-PD-1 therapy.

• 4-Phenylbutyric Acid (4-PBA): Precision Modulation of ER Str

  2026-05-03

  Explore how 4-Phenylbutyric acid (4-PBA) enables targeted ER stress alleviation in complex cellular models. This article reveals practical assay insights and advances in apoptosis and autophagy research, grounded in the latest scientific evidence.

• Optimizing MTT Cell Viability Assays: Applied Use-Cases & Pr

  2026-05-02

  Unlock the full potential of MTT as a colorimetric cell viability assay reagent by leveraging high-purity APExBIO MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide) in advanced workflows. Discover actionable protocol optimizations and troubleshooting tips informed by recent research breakthroughs in neurodegeneration.

• Bile Acid Metabolism Subtypes Reveal Key CRC Prognostic Mark

  2026-05-01

  Feng et al. (2026) identified molecular subtypes of colorectal cancer (CRC) based on bile acid metabolism and highlighted three genes—CLCA1, UGT2A3, and ZG16—as markers of immune dysfunction and prognosis. This integrative approach provides mechanistic insight into CRC tumor microenvironment heterogeneity and offers validated gene expression markers for future translational research.

• Fosinopril Sodium: Advanced ACE Inhibition for Hypertension

  2026-05-01

  Fosinopril sodium stands out as a phosphinic acid-based ACE inhibitor, offering dual renal and hepatic elimination and robust zinc ion targeting for reproducible hypertension and cardiovascular research. Leverage APExBIO’s high-purity formulation for streamlined experimental workflows, precise pharmacokinetic modeling, and optimized renal hemodynamics studies.

• Applied Protocols for (-)-Epigallocatechin gallate (EGCG) Re

  2026-04-30

  Harness the multifunctional potential of (-)-Epigallocatechin gallate (EGCG) for advanced bone regeneration, apoptosis assays, and antiviral investigations. This guide translates the latest scaffold-based delivery breakthroughs and troubleshooting tips into actionable, data-driven workflows for biomedical researchers.

• PSMD14-CARM1 Axis Drives HCC Progression via FERMT1 Activati

  2026-04-30

  This study reveals that PSMD14-mediated deubiquitination stabilizes CARM1, which in turn transcriptionally activates FERMT1 through H3R17 methylation, promoting hepatocellular carcinoma (HCC) proliferation and metastasis. These findings identify the PSMD14-CARM1-FERMT1 pathway as a potential therapeutic target for HCC intervention.

• Precision in Src Kinase Pathway Research: PP 3 as Gold Stand

  2026-04-29

  This thought-leadership article explores the mechanistic and strategic imperatives of using 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (PP 3) as a rigorously validated negative control in Src kinase signaling pathway research. Drawing on the latest vascular biology insights, including landmark studies in NADPH oxidase-derived ROS signaling, the article provides actionable guidance for translational researchers seeking specificity and reproducibility in kinase inhibitor assays. The discussion synthesizes evidence from peer-reviewed literature and leading content assets, while positioning APExBIO’s PP 3 as the definitive research tool for advancing cell signaling studies.

• Dual-Metric In Vitro Evaluation of Cancer Drug Responses

  2026-04-29

  Schwartz’s dissertation introduces a dual-metric framework to distinguish proliferative arrest from cell death during in vitro anti-cancer drug testing. This approach improves the granularity and functional interpretation of angiogenesis inhibition assays and supports more accurate evaluation of VEGF pathway modulators such as Axitinib.

• Streptavidin – Cy5: Precision Biotin Detection in Oncology A

  2026-04-28

  Streptavidin – Cy5 empowers researchers with ultrasensitive, high-content biotin detection across immunohistochemistry, flow cytometry, and in situ hybridization. Its robust Cy5 fluorescent dye conjugation ensures strong signal and reproducibility in translational cancer research, streamlining workflows and troubleshooting.

• Exosomal miR-21-5p Mitigates Cisplatin-Induced Ovarian Cell

  2026-04-28

  This study demonstrates that exosomes from placental mesenchymal stem cells (PMSC-Exos) deliver miR-21-5p to ovarian granulosa cells, suppressing apoptosis by modulating the PTEN/AKT/mTOR signaling axis. The findings provide a mechanistic advance for cell-free therapeutic strategies against premature ovarian insufficiency (POI), especially in the context of chemotherapy-induced ovarian injury.

15210 records 2/1014 page Previous Next 12345 下5页 Last page